Citations

Clear

3138 citation(s) found for "Smith, AM".

DNASE-MEDIATED DISSOLUTION OF NEUTROPHIL EXTRACELLULAR TRAPS ACCELERATES IN VITRO THROMBIN GENERATION KINETICS IN TRAUMA PATIENTS
Goswami, Julie , Mahony, C , Kizhakkedathu, Jayachandran N. , Vappala, Sreeparna , Morrissey, James H. , Spears, Grant M. , Bailey, Kent R. , Dong, Jing‐fei , Kozar, Rosemary A. , Hall, Nathan W , Johnstone, Andrea L. , Park, Myung S., MacArthur, Taleen A. , Mahony, Cillian, Smith, Stephanie A.

Mayo Clinic

Shock | August 12, 2022 | Volume: 58 | Issue: 3 | Pages: 217-223

10.1097/shk.0000000000001972 | PMID 35959777 Get It

ABSTRACT Introduction: Neutrophil extracellular traps (NETs) trigger thrombin generation. We aimed to characterize the effects of deoxyribonuclease (DNAse) on NET components (cell-free DNA [cfDNA] and histones) and thrombin generation after trauma. Methods: Citrated plasma samples were collected from trauma patients and healthy volunteers. Thrombin generation (calibrated automated thrombogram) was measured as lag time (LT, in minutes), peak height (in nM), and time to peak thrombin generation (in minutes). Citrullinated histone 3 (CitH3) and 4 (CitH4) were measured by enzyme-linked immunosorbent assay; cfDNA by PicoGreen (all in nanograms per milliliter). Samples analyzed +/− DNAse (1,000 U/mL). Results expressed as median and quartiles [Q1, Q3], Wilcoxon testing, P < 0.05 significant. Results: We enrolled 46 patients (age, 48 [31, 67] years; 67% male) and 21 volunteers (age, 45 [28, 53] years; 43% male). Deoxyribonuclease treatment of trauma plasma led to shorter LT (3.11 [2.67, 3.52] min; 2.93 [2.67, 3.19] min), shorter time to peak thrombin generation (6.00 [5.30, 6.67] min; 5.48 [5.00, 6.00] min), greater peak height (273.7 [230.7, 300.5] nM; 288.7 [257.6, 319.2] nM), decreased cfDNA (576.9 [503.3, 803.1] ng/mL; 456.0 [393.5, 626.7] ng/mL), decreased CitH3 (4.54 [2.23, 10.01] ng/mL; 3.59 [1.93, 7.98] ng/mL), and increased H4 (1.30 [0.64, 6.36] ng/mL; 1.75 [0.83, 9.67] ng/mL), all P < 0.001. The effect of DNAse was greater on trauma patients as compared with volunteers for LT (ΔLT, −0.21 vs. −0.02 min, P = 0.007), cfDNA (ΔcfDNA −133.4 vs. −84.9 ng/mL, P < 0.001), and CitH3 (ΔCitH3, –0.65 vs. −0.11 ng/mL, P = 0.004). Conclusion: Deoxyribonuclease treatment accelerates thrombin generation kinetics in trauma patient samples as compared with healthy volunteers. These findings suggest that NETs may contribute to the hypercoagulable state observed in trauma patients.
Epidemiology and Financial Burden of Adult Chronic Hypoparathyroidism
Björnsdóttir, Sigríður , Ing, Steven , Mitchell, Deborah M. , Sikjær, Tanja , Underbjerg, Line , Hassan‐Smith, Zaki , Sfeir, Jad , Gittoes, Neil , Clarke, B.L. , Gittoes, Neil J , Clarke, Bart L , Sfeir, Jad G

Mayo Clinic

Journal of Bone and Mineral Research | August 12, 2022 | Volume: 37 | Issue: 12 | Pages: 2602-2614

10.1002/jbmr.4675 | PMID 36054571 Get It

ABSTRACT Chronic hypoparathyroidism is characterized by low serum calcium, increased serum phosphorus, and inappropriately low or decreased serum parathyroid hormone. This rare disorder is associated with a variety of complications. The prevalence, incidence, mortality, financial burden, and epidemiology of complications of this disorder are not well understood. This narrative review summarizes current information on the epidemiology and complications of chronic hypoparathyroidism. The reported prevalence of chronic hypoparathyroidism ranges from 6.4–37/100,000, and the incidence is reported to be 0.8–2.3/100,000/year. Mortality is not increased in studies from Denmark or South Korea but was increased in studies from Scotland and Sweden. The financial burden of this disorder is substantial because of increased health care resource utilization in two studies but not well quantitated. Recognized complications include hypercalciuria, nephrocalcinosis, kidney stones, and chronic kidney disease; low bone turnover and possibly upper extremity fractures; cardiac and vascular calcifications; basal ganglia calcifications, cataracts, infections, neuropsychiatric complications, and difficulties with pregnancy. This review concludes that chronic hypoparathyroidism is a rare disorder associated with significant morbidity that may not increase overall mortality but is associated with a substantial financial burden. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
Heterozygous NOTCH1 Variants Cause CNS Immune Activation and Microangiopathy
Helman, Guy , Zarekiani, Parand , Tromp, Samantha A. M., Andrews, Ashley , Bonkowsky, Joshua L. , Chassevent, Anna , Giorgio, Elisa , Pippucci, Tommaso , Wei, Shen, Smith‐Hicks, Constance , Vaula, Giovanna , Schimmel, Mareike , Vollert, Kurt, Shimizu, Fumitaka , Kanda, Takashi , Lynch, Matthew , Roscioli, Tony , Taft, Ryan J. , Simons, Cas , Bugiani, Marianna , Shen, Wei , Bonkowsky, Joshua L , Willemsen, Michèl A A P , Shimizu, Fumitaka , van der Knaap, Marjo S , Shen, Wei , Giorgio, Elisa , Simons, Cas , Botto, Lorenzo D. , Kuijpers, Taco Willem , Knaap, Marjo S. van der

Mayo Clinic

Annals of Neurology | August 10, 2022 | Volume: 92 | Issue: 5 | Pages: 895-901

10.1002/ana.26477 | PMID 35947102 Get It

NOTCH1 belongs to the NOTCH family of proteins that regulate cell fate and inflammatory responses. Somatic and germline NOTCH1 variants have been implicated in cancer, Adams‐Oliver syndrome, and cardiovascular defects. We describe 7 unrelated patients grouped by the presence of leukoencephalopathy with calcifications and heterozygous de novo gain‐of‐function variants in NOTCH1. Immunologic profiling showed upregulated CSF IP‐10, a cytokine secreted downstream of NOTCH1 signaling. Autopsy revealed extensive leukoencephalopathy and microangiopathy with vascular calcifications. This evidence implicates that heterozygous gain‐of‐function variants in NOTCH1 lead to a chronic central nervous system (CNS) inflammatory response resulting in a calcifying microangiopathy with leukoencephalopathy. ANN NEUROL 2022;92:895–901
Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma
Bewicke‐Copley, Findlay , Korfi, Koorosh , Araf, Shamzah, Hodkinson, Brendan P. , Kumar, Emil , Cummin, Thomas , Ashton‐Key, Margaret , Barrans, Sharon, Hoppe, Suzan van, Burton, Cathy , Elshiekh, Mohamed , Rule, Simon , Crosbie, Nicola, Clear, Andrew , Calaminici, Maria , Runge, Hendrik F.P. , Hills, Robert K. , Sha, Chulin , Painter, Daniel , Smith, Alexandra , Naresh, Kikkeri N. , Westhead, David R. , Steele, Andrew J. , Hodson, Daniel J. , Balasubramanian, Sriram , Runge, Hendrik , Scott, David W , Nagano, Ai , Davies, Andrew , Painter, Daniel , Smith, Alexandra , Gribben, John G. , Westhead, David R , Okosun, Jessica , Steele, Andrew , Hodson, Daniel J , Johnson, Peter , Wang, Jun , Fitzgibbon, Jude , Naresh, Kikkeri N , Scott, David W. , Rimsza, Lisa M. , Menon, Geetha, Davies, John R., Davies, Andrew , Johnson, Peter , Fitzgibbon, Jude

Mayo Clinic

Blood Advances | August 10, 2022 | Volume: 7 | Issue: 5 | Pages: 845-855

10.1182/bloodadvances.2022007536 | PMID 35947123 Get It

Abstract Despite the effectiveness of immuno-chemotherapy, 40% of patients with diffuse large B-cell lymphoma (DLBCL) experience relapse or refractory disease. Longitudinal studies have previously focused on the mutational landscape of relapse but fell short of providing a consistent relapse-specific genetic signature. In our study, we have focused attention on the changes in GEP accompanying DLBCL relapse using archival paired diagnostic/relapse specimens from 38 de novo patients with DLBCL. COO remained stable from diagnosis to relapse in 80% of patients, with only a single patient showing COO switching from activated B-cell–like (ABC) to germinal center B-cell–like (GCB). Analysis of the transcriptomic changes that occur following relapse suggest ABC and GCB relapses are mediated via different mechanisms. We developed a 30-gene discriminator for ABC–DLBCLs derived from relapse-associated genes that defined clinically distinct high- and low-risk subgroups in ABC–DLBCLs at diagnosis in datasets comprising both population-based and clinical trial cohorts. This signature also identified a population of &lt;60-year–old patients with superior PFS and OS treated with ibrutinib–R-CHOP as part of the PHOENIX trial. Altogether this new signature adds to the existing toolkit of putative genetic predictors now available in DLBCL that can be readily assessed as part of prospective clinical trials.
BNT162b2 mRNA Vaccination Against Coronavirus Disease 2019 is Associated With a Decreased Likelihood of Multisystem Inflammatory Syndrome in Children Aged 5–18 Years—United States, July 2021 – April 2022
Zambrano, Laura D. , Newhams, Margaret M. , Olson, Samantha M. , Halasa, Natasha , Price, Ashley M. , Orzel, Amber, Boom, Julie A. , Bline, Katherine , Kamidani, Satoshi , Tarquinio, Keiko M. , Schuster, Jennifer E. , Cullimore, Melissa L. , Heidemann, Sabrina M. , Nofziger, Ryan A. , Cameron, Melissa A. , Walker, Tracie C. , Michelson, Kelly N, Coates, Bria M. , Flori, Heidi R. , Mack, Elizabeth H. , Smallcomb, Laura , Gertz, Shira J. , Bhumbra, Samina S. , Bradford, Tamara T. , Levy, Emily R. , Kong, Michele , Irby, Katherine, Zinter, Matt S. , Bowens, Cindy, Crandall, Hillary , Hume, Janet R. , Patel, Manish M, Campbell, Angela P. , Randolph, Adrienne G. , Investigators, for the Overcoming COVID-19, Murdock, Meghan, Gaspers, Mary Glas , Kelley, Connor P. , Irby, Katherine, Sanders, Ronald C., Yates, Masson, Smith, Chelsea , Crane, Katheryn, Lionetti, Geraldina, Murcia-Montoya, Juliana, Villarreal-Chico, Denise, Skura, Adam L., Hakimi, Daniel , Peralta, Harvey, Sea, Yea Ji, Mrotek, Kennis-Grace, Lockwood, Justin M. , Port, Emily, Carson, Imogene A., Chatani, Brandon , Kamidani, Satoshi, Hussaini, Laila, Baida, Nadine, Michelson, Kelly N, Rhodes, Simone T., Khan, Hassan A, Rowan, Courtney M. , Stumpf, Mary, Johnston, Marla , Newhams, Margaret M, Kücükak, Suden, Orzel, Amber O, Chen, Sabrina R., Boutselis, Benjamin J., McCadden, Timothy P. , Stewart, Kasey R, Weller, Edie, Berbert, Laura , He, Jie , Bruno, Ellen R., Goertzen, Lexie A., Drapeau, Noelle M., Martin, Lora , Malloch, Lacy , Harrison, Virginia A., Sanders, Cameron , Patterson, Kayla , Chikere, Chidinma A, Kietzman, Abigail , Sullivan, Melissa, Rinehart, Valerie H., Hoody, Lauren A., Bennett, Paris C., Twinem, Nicole A., Tomcany, Merry, Staat, Mary Allen , Rohlfs, Chelsea C., Wolfe, Amber, Chiotos, Kathleen, Douglas, Rebecca L. , Phengchomphet, Kathlyn, Bickford, Megan M., Wakefield, Lauren E., Hayek, Haya , Romero, Yesenia, Boom, Julie A, Oates, Jennifer N., Maamari, Mia , Bowens, Cindy, Olson, Mady, Zambrano, Laura D, Patel, Manish M, Kamidani, Satoshi , Levy, Emily R , Randolph, Adrienne G , Kong, Michele , Hume, Janet R , Zambrano, Laura D , Staat, Mary A , Gertz, Shira J , Bline, Katherine E , Young, Cameron C. , Sahni, Leila C , Maddux, Aline B. , Chiotos, Kathleen , Hobbs, Charlotte V. , Pannaraj, Pia S. , Schwartz, Stephanie P. , Michelson, Kelly N, Irby, Katherine, Cvijanovich, Natalie Z , Bowens, Cindy, Patel, Manish M, Investigators, for the Overcoming COVID-19, Typpo, Katri , Irby, Katherine, Kamidani, Satoshi, Michelson, Kelly N, Newhams, Margaret M, Orzel, Amber O, Moran, Patrick, Behl, Supriya , Chiotos, Kathleen, Boom, Julie A, Bowens, Cindy, Olson, M, Zambrano, Laura D, Patel, Manish M

Mayo Clinic

Clinical Infectious Diseases | August 4, 2022 | Volume: 76 | Issue: 3 | Pages: e90-e100

10.1093/cid/ciac637 | PMID 35924406 Get It

Abstract Background Multisystem inflammatory syndrome in children (MIS-C), linked to antecedent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is associated with considerable morbidity. Prevention of SARS-CoV-2 infection or coronavirus disease 2019 (COVID-19) by vaccination might also decrease MIS-C likelihood. Methods In a multicenter, case-control, public health investigation of children ages 5–18 years hospitalized from 1 July 2021 to 7 April 2022, we compared the odds of being fully vaccinated (2 doses of BNT162b2 vaccine ≥28 days before hospital admission) between MIS-C case-patients and hospital-based controls who tested negative for SARS-CoV-2. These associations were examined by age group, timing of vaccination, and periods of Delta and Omicron variant predominance using multivariable logistic regression. Results We compared 304 MIS-C case-patients (280 [92%] unvaccinated) with 502 controls (346 [69%] unvaccinated). MIS-C was associated with decreased likelihood of vaccination (adjusted OR [aOR]: .16; 95% CI: .10–.26), including among children ages 5–11 years (aOR: .22; 95% CI: .10–.52), ages 12–18 years (aOR: .10; 95% CI: .05–.19), and during the Delta (aOR: .06; 95% CI: .02–.15) and Omicron (aOR: .22; 95% CI: .11–.42) variant-predominant periods. This association persisted beyond 120 days after the second dose (aOR: .08; 95% CI: .03–.22) in 12–18-year-olds. Among all MIS-C case-patients, 187 (62%) required intensive care unit admission and 280 (92%) vaccine-eligible case-patients were unvaccinated. Conclusions Vaccination with 2 doses of BNT162b2 is associated with reduced likelihood of MIS-C in children ages 5–18 years. Most vaccine-eligible hospitalized patients with MIS-C were unvaccinated.
Prognostic Implications of a Morphometric Evaluation for Chronic Changes on All Diagnostic Native Kidney Biopsies
Đenić, Aleksandar , Bogojevic, Marija , Sabov, Moldovan, Asghar, Muhammad Sohaib , Sethi, Sanjeev , Fervenza, Fernando C. , Glassock, Richard J. , Asghar, Muhammad S , Rule, Andrew D , Fervenza, Fernando C , Denic, Aleksandar , Mullan, Aidan F. , Smith, Maxwell L. , Hommos, Musab S. , Rule, Andrew D.

Mayo Clinic

Journal of the American Society of Nephrology | August 3, 2022 | Volume: 33 | Issue: 10 | Pages: 1927-1941

10.1681/asn.2022030234 | PMID 35922132 Get It

Background Semiquantitative visual inspection for glomerulosclerosis, interstitial fibrosis, and arteriosclerosis is often used to assess chronic changes in native kidney biopsies. Morphometric evaluation of these and other chronic changes may improve the prognostic assessment. Methods We studied a historical cohort of patients who underwent a native kidney biopsy between 1993 and 2015 and were followed through 2021 for ESKD and for progressive CKD (defined as experiencing 50% eGFR decline, temporary dialysis, or ESKD). Pathologist scores for the percentages of globally sclerosed glomeruli (GSG), interstitial fibrosis and tubular atrophy (IFTA), and arteriosclerosis (luminal stenosis) were available. We scanned biopsy sections into high-resolution images to trace microstructures. Morphometry measures were percentage of GSG; percentage of glomerulosclerosis (percentage of GSG, ischemic-appearing glomeruli, or segmentally sclerosed glomeruli); percentage of IFTA; IFTA foci density; percentage of artery luminal stenosis; arteriolar hyalinosis counts; and measures of nephron size. Models assessed risk of ESKD or progressive CKD with biopsy measures adjusted for age, hypertension, diabetes, body mass index, eGFR, and proteinuria. Results Of 353 patients (followed for a median 7.5 years), 75 developed ESKD and 139 experienced progressive CKD events. Visually estimated scores by pathologists versus morphometry measures for percentages of GSG, IFTA, and luminal stenosis did not substantively differ in predicting outcomes. However, adding percentage of glomerulosclerosis, IFTA foci density, and arteriolar hyalinosis improved outcome prediction. A 10-point score using percentage of glomerulosclerosis, percentage of IFTA, IFTA foci density, and any arteriolar hyalinosis outperformed a 10-point score based on percentages of GSG, IFTA, and luminal stenosis >50% in discriminating risk of ESKD or progressive CKD. Conclusion Morphometric characterization of glomerulosclerosis, IFTA, and arteriolar hyalinosis on kidney biopsy improves prediction of long-term kidney outcomes.
Surgical Pathology of Diffuse Parenchymal Lung Disease in Patients With Psoriasis or Psoriatic Arthritis
Butt, Yasmeen M. , Tazelaar, Henry D. , Roden, Anja C. , Larsen, Brandon T. , Smith, Maxwell L. , Tazelaar, Henry D. , Mengoli, Maria Cecilia

Mayo Clinic

Archives of Pathology & Laboratory Medicine | August 2, 2022 | Volume: 147 | Issue: 5 | Pages: 525-533

10.5858/arpa.2021-0616-oa | PMID 35917487 Get It

Context.— Diffuse parenchymal lung disease (DPLD) is a well-recognized complication of systemic connective tissue disease (CTD) but rarely arises in patients with psoriasis or psoriatic arthritis, a poorly understood phenomenon. Objective.— To characterize DPLD associated with psoriasis or psoriatic arthritis, with or without prior immunomodulation. Design.— Pathology consultation files were searched for patients having psoriasis or psoriatic arthritis and DPLD. After excluding cases with active infection or smoking-related DPLD only, 44 patients (22 women; median age, 60 years; range, 23–81 years) were enrolled. Clinical history and pathology slides were reviewed. Results.— Twenty-seven of 44 patients (61%) had psoriatic arthritis; the remainder had psoriasis alone. Most presented many years later with nonspecific respiratory symptoms. Nearly one-third had no prior immunosuppression, and most had no concomitant CTD. Radiographically, ground-glass opacities, consolidation, and/or reticulation were typical. Histologically, nonspecific interstitial pneumonia and unclassifiable fibrosis were seen in 24 patients (55%) and 8 patients (18%), respectively; usual interstitial pneumonia and airway-centered fibrosis were rare. Superimposed acute lung injury was common, usually manifesting as organizing pneumonia. Lymphoplasmacytic infiltrates, lymphoid aggregates, and chronic pleuritis were frequent. Interstitial granulomas were seen in 17 patients (39%) but were usually rare, poorly formed, and nonnecrotizing. No histologic differences were apparent among patients with or without concomitant CTDs or prior therapy. Conclusions.— Some patients with psoriasis or psoriatic arthritis develop clinically significant DPLD, even without prior therapy. Histopathologic findings mirror changes seen with other CTDs. Additional studies are warranted to clarify the association between psoriasis or psoriatic arthritis and DPLD.
Robotic-assisted Bronchoscopy to Diagnose Malakoplakia
Sakata, Kenneth K. , Azadeh, Natalya , Kim, Jeeho , Smith, Maxwell L.

Mayo Clinic

Journal of Bronchology & Interventional Pulmonology | August 2, 2022 | Volume: 30 | Issue: 2 | Pages: 174-176

10.1097/lbr.0000000000000861 | PMID 35916425 Get It

Genomic and phenomic landscape of clonal hematopoiesis in over a million ancestrally diverse participants
Uddin, Md Mesbah , Weinstock, Joshua S. , Niroula, Abhishek , Vlasschaert, Caitlyn , Koyama, Satoshi , Nakao, Tetsushi , Urbut, Sarah , Paruchuri, Kaavya , Silver, Alexander J. , Mack, Taralynn , Wong, Megan , Bhattacharya, Romit , Jorshery, Saman Doroodgar , Raddatz, Michael A. , Hornsby, Whitney , Kresge, Hailey A. , Cho, Kelly , Sun, Yan V. , Pyarajan, Saiju , Chen, Yii‐Der Ida , Sheu, Wayne H-H , Hung, Yi‐Jen , Hidalgo, Bertha , Fornage, Myriam , Kaplan, Robert C., Williams, L. Keoki , Province, Mike , Kardia, Sharon, Peyser, Patricia A., Yanek, Lisa R. , Becker, Lewis C. , Meyers, Deborah A. , Naseri, Take, Barnes, Kathleen C. , Redline, S S, Schwartz, D A, Shoemaker, M. Benjamin , Palmer, Nicholette D., Bowden, Donald W., Kumar, Rajesh, Nj, Smith, Floyd, James, Tracy, Russell, Bis, Joshua C. , SS, Rich, Boerwinkle, Eric, Wang, Zhe, Silverman, Edwin K. , Auer, Paul L. , Reiner, Alexander P. , Ebert, Benjamin L. , Natarajan, Pradeep , Uddin, Md M , Niroula, Abhishek , Weinstock, Joshua S , Bhattacharya, Romit , Ebert, Benjamin L , Natarajan, Pradeep , Yu, Zhi , Zekavat, Seyedeh M , Truong, Buu Minh Thanh , Haidermota, Sara , Honigberg, Michael C. , Zhang, Martin Jinye , Dron, Jacqueline S. , Heimlich, Jonathan Brett , Sankaran, Vijay G. , Griffin, Gabriel K. , Gibson, Christopher James , Wilson, Peter W.F. , Genovese, Giulio , Xu, Yaomin , Savona, Michael R. , Raffield, Laura M. , Arnett, Donna K. , Konkle, Barbara A. , Peyser, Patricia A. , Smith, Jennifer A. , Mathias, Rasika A. , Andrade, Mariza de , Darbar, Dawood , He, Jiang , Blangero, John , Weiss, Scott T. , Custer, Brian , Minster, Ryan L , Viali, Satupaitea , Mitchell, Braxton D. , Palmer, Nicholette D , Freedman, Barry I. , Bowden, Donald W. , Albert, Christine M. , Smith, Nicholas, Tracy, Russell P. , Psaty, Bruce M. , Taylor, Kent D. , Rotter, Jerome I. , Boerwinkle, Eric , Vasan, Ramachandran S. , Lubitz, Steven A. , Ellinor, Patrick T. , Loos, Ruth J. F. , Yun, Jeong H. , Cho, Michael H. , Abecasis, Gonçalo R. , Kooperberg, Charles , Reiner, Alex P. , Jaiswal, Siddhartha , Bick, Alexander G.

Mayo Clinic

No container title available | July 31, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2022.07.29.22278015 Get It

Abstract With aging, somatic mutations in hematopoietic stem and progenitor cells (HSPC) can give rise to clonal hematopoiesis of indeterminate potential (CHIP), a premalignant state associated with diverse age-related diseases. Here we report the largest multi-ancestry genome-wide analysis of CHIP to date (N = 1,018,305), including individuals of African (N = 85,978), Admixed American (N = 191,371), East Asian (N = 13,532), European (N = 694,015), and South Asian (N = 13,193) ancestry. Multi-ancestry meta-analyses identified 72 genome-wide significant loci, including 44 novel associations implicating genes such as AFF1 , ATF7IP , ATP8B4 , BCL2 , CEBPA , CYRIA , DNM2 , ELF1 , NKX2-3 , PIK3CB , PRDM16 , RPN1 , TERC , and TRIM4 . Notably, variants at MECOM and PHF20L1 showed opposite allelic effects between DNMT3A - and non- DNMT3A -driven CHIP, highlighting driver-specific germline influences. Implicated loci converge on pathways regulating telomere maintenance, cell-cycle control, hematopoietic transcription, DNA damage response and immune signaling. These findings support a model in which germline variation both expands the HSPC pool and biases clonal selection in a driver-dependent manner, providing a mechanistic basis for inter-individual heterogeneity in CHIP. Phenome-wide association analyses further linked CHIP to hematologic, neoplastic, and circulatory traits, with enrichment across hematopoietic and non-hematopoietic cell types. Together, this work expands the genomic and phenomic landscape of CHIP and reveals germline–somatic interactions that shape clonal evolution during aging.
Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project
Midgette, Bria, Strunk, Andrew , Akilov, Oleg E. , Ardon, Christine B. , Cohen, Arnon D. , Cohen, Steven A. , Daveluy, Steven , Delage, M. , Esmann, Solveig, Fisher, Shani , Głowaczewska, Amelia , Brant, Elena Gonzalez, Guilbault, Sandra , Hughes, Rosalind , Ingram, John R , Jemec, Gregor B. E. , Ju, Qiang , Kappe, Naomi , Kirby, Joslyn S. , Matusiak, Łukasz , Micha, Stella, Miller, Angela P., Moseng, Dagfinn, Naik, Haley B. , Nassif, Aude , Nikolakis, Georgios , Pascual, J.C. , Resnik, Barry I., Riad, Hassan, Sayed, Christopher J. , Soliman, Yssra , Szepietowski, Jacek C. , Thorlacius, Linnea , Zee, Hessel H. van der , Villumsen, Bente , Wang, Lanqi , Garg, Amit , Cohen, Steven , Daveluy, Steven , Ingram, J R , Jemec, G B E , Micheletti, Robert , Naik, Haley , Paek, So Yeon , Sayed, Christopher , Szepietowski, Jacek C , Wang, Lanqi , Garg, Amit , Thorlacius, L , Akilov, Oleg E , van der Zee, Hessel H , Alavi, Afsáneh , Bechara, Falk G. , Mármol, V. del , Giamarellos‐Bourboulis, Evangelos J. , Goldfarb, Noah , Grimstad, Øystein , Hamzavi, Iltefat H. , Kirby, Brian , Lowes, Michelle A , Paek, So Yeon , Prens, Errol P. , Smith, Saxon D. , Tan, Jerry K.L. , Tzellos, Thrasyvoulos , Zouboulis, Christos C.

Mayo Clinic

British Journal of Dermatology | July 30, 2022 | Volume: 187 | Issue: 6 | Pages: 927-935

10.1111/bjd.21798 | PMID 36056741 Get It

Abstract Background Nearly half of patients with hidradenitis suppurativa (HS) report dissatisfaction with their treatment. However, factors related to treatment satisfaction have not been explored. Objectives To measure associations between treatment satisfaction and clinical and treatment-related characteristics among patients with HS. Methods Treatment satisfaction was evaluated utilizing data from a cross-sectional global survey of patients with HS recruited from 27 institutions, mainly HS referral centres, in 14 different countries from October 2017 to July 2018. The primary outcome was patients’ self-reported overall satisfaction with their current treatments for HS, rated on a five-point scale from ‘very dissatisfied’ to ‘very satisfied’. Results The final analysis cohort comprised 1418 patients with HS, most of whom were European (55%, 780 of 1418) or North American (38%, 542 of 1418), and female (85%, 1210 of 1418). Overall, 45% (640 of 1418) of participants were either dissatisfied or very dissatisfied with their current medical treatment. In adjusted analysis, patients primarily treated by a dermatologist for HS had 1·99 [95% confidence interval (CI) 1·62–2·44, P &lt; 0·001] times the odds of being satisfied with current treatment than participants not primarily treated by a dermatologist. Treatment with biologics was associated with higher satisfaction [odds ratio (OR) 2·36, 95% CI 1·74–3·19, P &lt; 0·001] relative to treatment with nonbiologic systemic medications. Factors associated with lower treatment satisfaction included smoking (OR 0·78, 95% CI 0·62–0·99; active vs. never), depression (OR 0·69, 95% CI 0·54–0·87), increasing number of comorbidities (OR 0·88 per comorbidity, 95% CI 0·81–0·96) and increasing flare frequency. Conclusions There are several factors that appear to positively influence satisfaction with treatment among patients with HS, including treatment by a dermatologist and treatment with a biologic medication. Factors that appear to lower treatment satisfaction include active smoking, depression, accumulation of comorbid conditions and increasing flare frequency. Awareness of these factors may support partnered decision making with the goal of improving treatment outcomes. What is already known about this topic? Nearly half of patients with hidradenitis suppurativa report dissatisfaction with their treatments. What does this study add? Satisfaction with treatment is increased by receiving care from a dermatologist and treatment with biologics.Satisfaction with treatment is decreased by tobacco smoking, accumulation of comorbid conditions including depression, and higher flare frequency. What are the clinical implications of this work? Awareness of the identified factors associated with poor treatment satisfaction may support partnered decision making and improve treatment outcomes.